Biotricity to Host Third Quarter Fiscal Year 2024 Financial Results and Business Update Call on February 21st
February 19, 2024
Medolife Rx Cancels Optional Reverse Split Previously Included in Filing
July 29, 2021
Related Post
-
-
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
February 15, 2024
-
Biotricity Advances Towards Breakeven Milestone – Set to Announce Record Margins and Operational Efficiency for Third Quarter of Fiscal Year 2024
February 14, 2024
-
Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider
February 14, 2024